{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:29:21Z","timestamp":1753889361092,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","award":["26-DRC-2013-08"],"award-info":[{"award-number":["26-DRC-2013-08"]}],"id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","award":["26-DRC-2012\u201325"],"award-info":[{"award-number":["26-DRC-2012\u201325"]}],"id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Percutaneous left atrial appendage (LAA) closure is an alternative to oral anticoagulation (OAC) for atrial fibrillation (AF) patients with high thromboembolism risk, particularly with contraindications to OAC. The LAA itself could possess proarrhythmogenic properties. As patients undergoing LAA closure could be candidates for cardioversion or ablation, we aimed to evaluate AF disease progression following LAA closure and the outcome of patients undergoing a rhythm control strategy after the procedure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The prospective multicenter French Nationwide Observational LAA Closure Registry (FLAAC) comprises 33 French interventional cardiology departments. Patients were included if they fulfilled the following criteria: history of non-valvular AF, successful LAA closure and long-term ECG follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 331 patients with successful LAA closure were enrolled in the study. Patients mean age was 75.4\u2009\u00b1\u20090.5\u00a0years. The study population was characterized by a high thromboembolic risk (CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u00a0score: 4.5\u2009\u00b1\u20090.1) and frequent comorbidities. The median follow-up was 11.9\u00a0months. One hundred and nineteen (36.0%) patients were in sinus rhythm (SR) at baseline. Among SR patients, documented AF was observed in 16 (13.4%) patients whereas 15 (7.1%) patients in AF at baseline restored SR, at the end of follow up. Finally, only 13 patients (4%) underwent procedures to restore SR without complications during the follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The vast majority of patients undergoing LAA closure have the same AF status at baseline and one year after the index procedure. During the follow-up, a very small proportion (4%) of our population underwent procedures to restore SR without complications whatever the post-procedural antithrombotic strategy was.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-01994-8","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:03:10Z","timestamp":1620036190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Atrial fibrillation evolution and rhythm control strategy following left appendage closure: new insights from the prospective FLAAC registry"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-2218","authenticated-orcid":false,"given":"Nicolas","family":"Lellouche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaele","family":"Arrouasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Ternacle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Sylvain","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Juliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Pasquie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarvinder","family":"Dhanjal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Teiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1994_CR1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/eurheartj\/ehs469","volume":"34","author":"T Andersson","year":"2013","unstructured":"Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995\u20132008: a Swedish nationwide long-term case control study. Eur Heart J. 2013;34:1061\u20137.","journal-title":"Eur Heart J"},{"key":"1994_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"1994_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113:359\u201364.","journal-title":"Am J Med"},{"key":"1994_CR4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.1949.02900440011003","volume":"140","author":"JL Madden","year":"1949","unstructured":"Madden JL. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. J Am Med Assoc. 1949;140:769\u201372.","journal-title":"J Am Med Assoc"},{"key":"1994_CR5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0735-1097(94)00396-8","volume":"25","author":"MF Stoddard","year":"1995","unstructured":"Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"DR Holmes","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, PROTECT AF Investigators, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009;374:534\u201342.","journal-title":"Lancet"},{"key":"1994_CR7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","volume":"127","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, PROTECT AF Investigators, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation. 2013;127:720\u20139.","journal-title":"Circulation"},{"key":"1994_CR8","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","volume":"312","author":"VY Reddy","year":"2014","unstructured":"Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, PROTECT AF Steering Committee and Investigators, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988\u201398.","journal-title":"JAMA"},{"key":"1994_CR9","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","volume":"61","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, M\u00f6bius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61:2551\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.109.928903","volume":"122","author":"L Di Biase","year":"2010","unstructured":"Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, Horton R, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122:109\u201318.","journal-title":"Circulation"},{"key":"1994_CR11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/europace\/eux005","volume":"19","author":"H Yorgun","year":"2017","unstructured":"Yorgun H, Canpolat U, Kocyigit D, \u00c7\u00f6teli C, Evranos B, Aytemir K. Left atrial appendage isolation in addition to pulmonary vein isolation in persistent atrial fibrillation: one-year clinical outcome after cryoballoon-based ablation. Europace. 2017;19:758\u201368.","journal-title":"Europace"},{"key":"1994_CR12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacep.2015.04.006","volume":"1","author":"D Lakkireddy","year":"2015","unstructured":"Lakkireddy D, Sridhar Mahankali A, Kanmanthareddy A, Lee R, Badhwar N, Bartus K, et al. Left atrial appendage ligation and ablation for persistent atrial fibrillation: the LAALA-AF registry. JACC Clin Electrophysiol. 2015;1:153\u201360.","journal-title":"JACC Clin Electrophysiol"},{"key":"1994_CR13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10840-016-0116-7","volume":"46","author":"HC Park","year":"2016","unstructured":"Park HC, Lee D, Shim J, Choi JI, Kim YH. The clinical efficacy of left atrial appendage isolation caused by extensive left atrial anterior wall ablation in patients with atrial fibrillation. J Interv Card Electrophysiol. 2016;46:287\u201397.","journal-title":"J Interv Card Electrophysiol"},{"key":"1994_CR14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, ESC Scientific Document Group, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J."},{"key":"1994_CR15","doi-asserted-by":"crossref","first-page":"e005841","DOI":"10.1161\/CIRCINTERVENTIONS.117.005841","volume":"11","author":"E Teiger","year":"2018","unstructured":"Teiger E, Thambo JB, Defaye P, Hermida JS, Abbey S, Klug D, French National Left Atrial Appendage Closure Registry (FLAAC) Investigators, et al. Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events. Circ Cardiovasc Interv. 2018;11:e005841.","journal-title":"Circ Cardiovasc Interv"},{"key":"1994_CR16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","volume":"60","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM199809033391003","volume":"339","author":"M Haissaguerre","year":"1998","unstructured":"Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659\u201366.","journal-title":"N Engl J Med"},{"key":"1994_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jacep.2019.08.012","volume":"6","author":"M Al Rawahi","year":"2020","unstructured":"Al Rawahi M, Liang JJ, Kapa S, Lin A, Shirai Y, Kuo L, et al. Incidence of left atrial appendage triggers in patients with atrial fibrillation undergoing catheter ablation. JACC Clin Electrophysiol. 2020;6:21\u201330.","journal-title":"JACC Clin Electrophysiol"},{"key":"1994_CR19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jacc.2017.01.014","volume":"69","author":"HS Lim","year":"2017","unstructured":"Lim HS, Hocini M, Dubois R, Denis A, Derval N, Zellerhoff S, et al. Complexity and distribution of drivers in relation to duration of persistent atrial fibrillation. J Am Coll Cardiol. 2017;69:1257\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2016.07.770","volume":"68","author":"L Di Biase","year":"2016","unstructured":"Di Biase L, Burkhardt JD, Mohanty P, Mohanty S, Sanchez JE, Trivedi C, et al. Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF trial. J Am Coll Cardiol. 2016;68:1929\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jacep.2017.07.007","volume":"4","author":"DJ Friedman","year":"2018","unstructured":"Friedman DJ, Black-Maier EW, Barnett AS, Pokorney SD, Al-Khatib SM, Jackson KP, et al. Left atrial appendage electrical isolation for treatment of recurrent atrial fibrillation: a meta-analysis. JACC Clin Electrophysiol. 2018;4:112\u201320.","journal-title":"JACC Clin Electrophysiol"},{"key":"1994_CR22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ahj.2004.09.053","volume":"149","author":"CR Kerr","year":"2005","unstructured":"Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489\u201396.","journal-title":"Am Heart J"},{"key":"1994_CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jacc.2009.11.040","volume":"55","author":"CB de Vos","year":"2010","unstructured":"de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/europace\/euw007","volume":"18","author":"G Fassini","year":"2016","unstructured":"Fassini G, Conti S, Moltrasio M, Maltagliati A, Tundo F, Riva S, et al. Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrial fibrillation. Europace. 2016;18:1705\u201310.","journal-title":"Europace"},{"key":"1994_CR25","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/europace\/euy025","volume":"20","author":"L Wintgens","year":"2018","unstructured":"Wintgens L, Romanov A, Phillips K, Ballesteros G, Swaans M, Folkeringa R, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace. 2018;20:1783\u20139.","journal-title":"Europace"},{"key":"1994_CR26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/jce.13838","volume":"30","author":"VK Gadiyaram","year":"2019","unstructured":"Gadiyaram VK, Mohanty S, Gianni C, Trivedi C, Al-Ahmad A, Burkhardt DJ, et al. Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage. J Cardiovasc Electrophysiol. 2019;30:511\u20136.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1994_CR27","first-page":"2094","volume":"16","author":"X Li","year":"2018","unstructured":"Li X, Li J, Chu H, Wang L, Shi L, Wang G, et al. Combination of catheter ablation for non-valvular atrial fibrillation and left atrial appendage occlusion in a single procedure. Exp Ther Med. 2018;16:2094\u2013100.","journal-title":"Exp Ther Med"},{"key":"1994_CR28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.athoracsur.2015.07.071","volume":"101","author":"MW Cullen","year":"2016","unstructured":"Cullen MW, Stulak JM, Li Z, Powell BD, White RD, Ammash NM, et al. Left atrial appendage patency at cardioversion after surgical left atrial appendage intervention. Ann Thorac Surg. 2016;101:675\u201381.","journal-title":"Ann Thorac Surg"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01994-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-01994-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01994-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:13:10Z","timestamp":1620036790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01994-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01994-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been approved by an ethics committee (CCTIRS, 24\/01\/2013, 13.023) and by the French data protection authority (CNIL, 21\/03\/2013; DR-2013-151). The study was performed in accordance with the ethical principles stated in the Declaration of Helsinki. All patients gave written inform consent prior to the procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Nicolas Lellouche declared to receive consulting fees from Abbott and Boston Scientific. Drs Teiger and Le Corvoisier received significant research grants from Boston Scientific and St. Jude Medical during the conduct of this study. The other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}